Nektar's rezpegaldesleukin shows durable hair regrowth in alopecia areata; Phase 3 ZENITH AA to start early 2027

NEKTAR THERAPEUTICS

Alopecia areata: SALT Score ≤20 response maintained in 75% (6/8) at 4 months off treatment and 63% (5/8) at 6 months; SALT ≤10 deepened from 7% at Week 52 to 19% off treatment.
REZOLVE-AA: Week 36-52, 29% low dose (18 µg/kg) and 31% high dose (24 µg/kg) achieved new SALT ≤20 vs none on placebo; 850-patient Phase 3 ZENITH AA starts early 2027.
Atopic dermatitis REZOLVE-AD: maintenance Q4W raised EASI-100 from 4% to 22%; Q12W from 9% to 18%; among prior responders, Q4W 6% to 30%, Q12W 14% to 27%.
Third Phase 3 ZENITH AD study initiated in treatment-experienced atopic dermatitis; safety through 52 weeks favorable and consistent with prior profile.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.